Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
August 29, 2017 09:05 ET
|
Abeona Therapeutics Inc
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapyBreakthrough Therapy designation enables priority review and expedites approval processEB-101 has demonstrated...
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
July 25, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
July 18, 2017 08:05 ET
|
Abeona Therapeutics Inc
Pivotal Phase 3 clinical trial is planned to commence in early 2018 EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and...
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 30, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 25, 2017 08:05 ET
|
Abeona Therapeutics Inc
Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
Abeona Therapeutics to Present at Multiple Upcoming Conferences
May 19, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...